Asthma, particularly in patients with inadequately controlled symptoms despite inhaled corticosteroid (ICS)-long-acting β2-agonist (LABA) therapy, continues to pose a significant treatment challenge, highlighting the need for more effective combination therapies. To address this gap, a clinical study evaluated the efficacy and safety of budesonide-glycopyrronium-formoterol fumarate dihydrate (BGF) delivered via Aerosphere co-suspension technology compared with budesonide-formoterol fumarate dihydrate using Aerosphere co-suspension delivery technology (BFFA) using Aerosphere and current suspension technology (Symbicort, BFFS) in 8,820 participants with asthma.
The study found that treatment with BGF met all pre-specified multiplicity-adjusted primary endpoints across regulatory comparisons in patients with Asthma. BGF 28·8 demonstrated significantly greater improvements in lung function…
